Patent ID: 8535676
Filing Date: 2013-09-17
Classification: A61K,A61P,C07K

Abstract:
1. A method for treating a CEA expressing cancer comprising: a) administering to a subject with a CEA expressing cancer a naked Class I monovalent anti-CEA monoclonal antibody (MAb) or antigen-binding fragment thereof; b) administering to the subject either concurrently or sequentially a naked Class III anti-CEA antibody or antigen-binding fragment thereof, wherein (i) the naked Class III anti-CEA antibody or fragment thereof is unreactive with human granulocytes; (ii) the naked Class III anti-CEA antibody or fragment thereof has human IgG1 hinge and constant regions; (iii) administration of the naked Class III anti-CEA antibody or fragment thereof to a subject with a cancer that expresses CEA antigen sensitizes the cancer to the subsequent administration of a therapeutic agent; and c) administering to the subject either concurrently or sequentially at least one therapeutic agent.